EP290/#660 First report of clinical outcomes with escalated doses of cisplatin and doxorubicin in PIPAC for peritoneal carcinomatosis of epithelial ovarian cancer

Abstract

survival estimates and Cox proportional hazards model adjusted for covariates were used for analyses. ResultsThe risks of recurrence of EOC increased steadily with increasing time from the start of primary treatment from 13.6% in 6-months to 71.0% after 12-months. In the final multivariate analyses, recurrence within 6 months of treatment was a significant independent predictor of poor OS in EOC patients (HR=7.23, 95%CI: 3.87-13.51, P<0.01). Conclusions Our study suggests that recurrence within 6months is an important prognostic factor that predicts poor OS in EOC. Early tumour recurrence may be a useful surrogate of overall survival and thus this information should be considered in the design of future tailored randomized controlled trials. Future strategies to improve OS in EOC patients should focus on identifying effective measures to prevent early tumour recurrence.

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial)

“…Regarding the recent literature data on PIPAC, 47 – 51 the strength of this manuscript lies in the fact that it is the first phase II trial on women with the same advanced disease (i.e., ovarian cancer), the biological characteristics (i.e., platinum-resistant), and the same number of previous lines of chemotherapies administered. Moreover, while the trial was ongoing, although different authors 49 , 50 performed dose-escalation studies that highlighted that PIPAC could be performed at the highest dosage, we decided to maintain the exact dosage according to Tempfer at al. 34 to guarantee more homogeneous results.…”